Dexrazoxane Hydrochloride is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated in cardiomyopathy and breast cancer and has 11 investigational indications. It is grouped under the following drug class(es): Topoisomerase inhibitors. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Dexrazoxane hydrochloride, Totect and Savene. Its PubChem CID is 6918223.
Cardioxane
| CAS No | 149003-01-0 |
|---|---|
| Molecular Formula | C11H17ClN4O4 |
| Molecular Weight | 304.73 g/mol |
| Synonyms | 4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione;hydrochloride |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Dexrazoxane Hydrochloride is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated in cardiomyopathy and breast cancer and has 11 investigational indications.
The listed CAS number is 149003-01-0.
The listed molecular formula is C11H17ClN4O4.
The listed molecular weight is 304.73 g/mol.
4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione;hydrochloride.
The source lists Dexrazoxane hydrochloride, Totect and Savene.